张启芳,禹文峰,吴昌学,官志忠,柏华
ZHANG Qifang,YU Wenfeng,WU Changxue,GUAN Zhizhong,BAI Hua

• 1:贵州医科大学分子生物学重点实验室
• 2:贵州医科大学第三附属医院医学实验中心

摘要(Abstract)：

目的:研究放疗联合抑制信号转导与转录激活因子3(STAT3)表达对恶性B细胞免疫原性的影响。方法:在BALB/c小鼠大腿皮下接种小鼠恶性B细胞淋巴瘤表达GFP的A20细胞形成肿瘤,在肿瘤内注射STAT3基因特异的shRNA质粒并进行放疗;采用荧光定量聚合酶链式反应(q PCR)和免疫印迹法(Western blot)方法分别检测肿瘤组织中STAT3 mRNA和蛋白表达水平;细胞膜蛋白分子染色法检测恶性B细胞表面分子MHCII、CD40和CD80的表达,用流式细胞仪收集细胞染色数据。结果:放疗联合抑制STAT3表达能显著降低STAT3 mRNA和蛋白表达水平,与单纯放疗比较,放疗联合抑制STAT3表达治疗显著增加A20细胞表面分子MHCII、CD40及CD80的表达水平,差异有统计学意义(P<0.05)。结论:放疗联合抑制STAT3表达能增强决定恶性B细胞免疫原性的分子表达。
Objective: To examine the effect of combination of radiotherapy with STAT3 inhibition on the immunogenicity of malignant B-cell Lymphoma Cells. Methods: Murine A20 B cell lymphoma cells were subcutaneously injected the thighs of BALB / c mice to form tumors. Tumors were given intratumor injection of STAT3 shRNA plasmid and local radiotherapy. STAT3 expression in tumors was determined by q PCR at mRNA levels and by Western blot at protein levels. The expression of MHCII,CD40 and CD80 were determined by extracellular staining and subsequent data collected by flow cytometry. Results: STAT3 expressions were remarkably silenced in tumors. Compared to radiotherapy alone,radiotherapy combined with STAT3 silencing significantly upregulated the expression of MHCII,CD40 and CD80 on A20 cells. Conclusions: Radiotherapy plus STAT3 silencing increases the expression of molecules that decide the immunogenicity of malignant B cell lymphoma.

关键词(KeyWords)： 信号转导与转录激活因子3;放射疗法;淋巴瘤,B细胞;聚合酶链式反应;免疫印迹;流式细胞术
signal transducer and activator of transcription 3;radiotherapy;lymphoma,B cell;polymerase chain reaction;western blot;flow cytometry

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(No.81560482);; 贵州省“2011协同创新中心”支助项目[黔教合协同创新中心(2014)06];; 贵州省科技厅重大专项[黔科合计Z字(2012)4010];; 贵州省科技厅科技计划项目[黔科合LG字(2012)009]

作者(Author): 张启芳,禹文峰,吴昌学,官志忠,柏华
ZHANG Qifang,YU Wenfeng,WU Changxue,GUAN Zhizhong,BAI Hua

DOI: 10.19367/j.cnki.1000-2707.2015.11.006

参考文献(References)：

• [1]Chen Y,Wang M,Romaguera J.Current regimens and novel agents for mantle cell lymphoma[J].Br J Haematol,2014(1):3-18.
• [2]Dreyling M,Amador V,Callana M,et al.Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma(MCL)-summary of the 12 annual conference of the EUROPEAN MCL NETWORK[J].Leuk Lymphoma,2014(4):1-26.
• [3]Foran JM,Cunningham D,Coiffier B,et al.Treatment of mantle-cell lymphoma with rituximab(chimeric monoclonal anti-CD20 antibody):analysis of factors associated with response[J].Ann Oncol,2000(Suppl 1):117-121.
• [4]Williams ME,Dreyling MH,Kahl BS,et al.Mantle cell lymphoma:report of the 2009 mantle cell lymphoma consortium workshop[J].Leuk Lymphoma,2010(3):390-398.
• [5]Dietrich S,Boumendil A,Finel H,et al.Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation:a retrospective study of the European Group for Blood and Marrow Transplantation(EBMT)[J].Ann Oncol,2014(5):1053-1058.
• [6]Sotomayor EM,Borrello I,Rattis FM,et al.Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression[J].Blood,2001(4):1070-1077.
• [7]Rabinovich GA,Gabrilovich D,Sotomayor EM.Immunosuppressive strategies that are mediated by tumor cells[J].Annu Rev Immunol,2007(25):267-296.
• [8]Cheng F,Wang H,Horna P,et al.Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells,leading to effective antitumor immunity[J].Cancer Res,2012(17):4440-4448.
• [9]Galluzzi L,Kepp O,Kroemer G.Immunogenic cell death in radiation therapy[J].Onco Immunology,2013(10):26536.
• [10]Vacchelli E,Vitale I,Tartour E,et al.Trial watch:anticancer radioimmunotherapy[J].Oncoimmunology,2013(9):25595.
• [11]Gao C,Kozlowska A,Nechaev S,et al.TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy[J].Cancer Res,2012(17):4440-4448.
• [12]Zhang Q,Hossain DM,Nechaev S,et al.TLR9mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo[J].Blood,2013(8):1304-1315.

文章评论(Comment)：